Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine the maximal tolerated dose level of lenalidomide
combined with fludarabine/rituximab in the therapy of patients with previously untreated
CD20-positive chronic lymphocytic leukemia. Following a dose escalation phase lenalidomide
will be given at the pre-determined maximum tolerated dose in combination with rituximab to
further determine the efficacy and tolerability of this regimen.